Part 1 featuring Victor Maertens, Government Affairs Manager at EUCOPE
In this episode Victor and Aparna will be focusing on Advanced Therapy Medicinal Products (ATMPs). We will start by looking at the main challenges for manufacturers in the ATMP approval process and what is required from an HTA perspective. We then discuss EUCOPE’s position paper on the different payment models, including the motivation for the report and key learnings. We look at sustainable patient access and whether the report addresses the affordability issues surrounding ATMP’s drug pricing and if this is even possible in the current landscape. The EU’s revision of Blood, Tissue & Cells legislation and lastly the future of ATMPs for manufacturers and patients.
Host: Aparna Krishnan
Guest speaker: Victor Maertens
Produced by: Operations team
About Victor Maertens:
https://www.linkedin.com/in/victormaertens/
Victor Maertens is the Government Affairs Manager for the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). Victor leads EUCOPE’s policy work on the Pharmaceutical Strategy and in the area of Cell and Gene Therapy. Prior to joining EUCOPE, Victor worked for Brussels-based consultancies, providing pharmaceutical companies, trade associations, and NGOs advocacy, strategy, and communications advice. His experience and interests include ATMPs, antimicrobial resistance, Orphan medicinal products (OMP), blood policy, and neglected tropical diseases.
About Eucope:
https://www.eucope.org/
For more than a decade, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) has been the voice of small to mid-sized health technology companies in Europe. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through innovative therapies and medical technology.
The Role of Patient Experience Data in Drug Development with Pina Haberl and Sam Morrison
World EPA Conference 2024 Special
Rare Disease Day Special 2024: The Role of Genetic Diagnosis in Rare Conditions with Nick Meade
Celebrating 5 Years of P4A: Reflections on Rare Diseases, Cell and Gene Therapies, and Legislation in Europe
Revolutionizing Patient Outcomes: The Power of Digital Health Solutions with RJ Kedziora
The Future of Patient Engagement and the Role of Technology in Healthcare with Iola Forster
Navigating the New EU HTA Regulation and Its Impact on ATMP Development
Alejandro Dorenbaum, CMO of Reneo Pharmaceuticals Discusses Clinical-Stage Therapies
Interview with Xortx Therapeutics CEO, Dr Allen Davidoff discussing their journey from early development to potential launch
World EPA Congress 2023 Special
Rare Disease Day Special 2023
Trends to look out for in 2023
World Orphan Drug Congress Europe 2022 Special
Winds of change for German Healthcare Market!
Part 2 -Patient Empowerment: Is it a no-brainer?
Part 1 Patient Empowerment; Why involving patients from early drug development through to launch is a no-brainer!
What makes P4A an award winning consultancy?
Special Episode with EUCOPE-Part 2 with Alexander Natz
China market access: obstacle or opportunity for orphan drug, cell and gene therapy manufacturers?
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain